(NASDAQ: CDXS) Codexis's forecast annual revenue growth rate of 25.55% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 78.36%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Codexis's revenue in 2025 is $57,164,000.On average, 4 Wall Street analysts forecast CDXS's revenue for 2025 to be $5,899,430,110, with the lowest CDXS revenue forecast at $5,670,602,088, and the highest CDXS revenue forecast at $6,002,786,356. On average, 4 Wall Street analysts forecast CDXS's revenue for 2026 to be $7,121,380,770, with the lowest CDXS revenue forecast at $6,788,113,293, and the highest CDXS revenue forecast at $7,904,721,822.
In 2027, CDXS is forecast to generate $11,705,884,732 in revenue, with the lowest revenue forecast at $11,705,884,732 and the highest revenue forecast at $11,705,884,732.